Dapagliflozin (heart failure with LVEF > 40 %) ' Addendum to Commission A23-11 1 Translation of addendum A 23-71 Dapagliflozin (Herzinsuffizienz mit LVEF > 40 %) – Addendum zum Projekt A23-11 (Dossierbewertung). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding . Dapagliflozin (heart failure with LVEF > 40 %) Addendum to Project A23-11 (dossier assessment)1 ADDENDUM Project: A23-71 Version: 1.0 Status: 27 July 2023 Addendum A23-71 Version 1.0 Dapagliflozin – Addendum to Project A23-11 27 July 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dapagliflozin (heart
Dapagliflozin (heart failure with preserved ejection fraction) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Dapagliflozin (Herzinsuffizienz mit LVEF > 40 %) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Dapagliflozin (heart failure with LVEF > 40%) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-11 Version: 1.0 Status: 30 May 2023 Extract of dossier assessment A23-11 Version 1.0 Dapagliflozin ( heart failure with LVEF > 40%) 30 May 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher
Dapagliflozin for treating chronic kidney disease PROSPEROInternational prospective register of systematic reviews Print | PDFEffectiveness of assisted standing on bone mineral density in children with cerebral palsy.Fernando Valenzuela, Teresa Balboa, Camila ReyesTo enable PROSPERO to focus on COVID-19 submissions, this registration record has undergone basic automated checks for eligibility
Dapagliflozin (Forxiga): For adults with chronic kidney disease (CKD). Published 07 April 2025 1 Advice document SMC2763 dapagliflozin film-coated tablets (Forxiga®) AstraZeneca UK Ltd 07 March 2025 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission dapagliflozin (Forxiga®) is accepted for restricted use within NHSScotland. Indication under review: in adults for the treatment of chronic kidney disease (CKD). SMC restriction: in patients having individually optimised standard care (including angiotensin converting enzyme inhibitors
Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to '35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Dapagliflozin (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 10 March 2022). Please note : This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-167 Dapagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier
Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V Dapagliflozin (Niereninsuffizienz) – Addendum zum Auftrag A21-109 Addendum 27.01.2022 1.0 Auftrag: A22-02 Version: Stand: IQWiG-Berichte – Nr. 1281 Addendum A22-02 Version 1.0 Dapagliflozin – Addendum zum Auftrag A21-109 27.01.2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG ) - i - Impressum Herausgeber Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Thema Dapagliflozin (Niereninsuffizienz) – Addendum zum Auftrag A21-109 Auftraggeber Gemeinsamer Bundesausschuss Datum des Auftrags 11.01.2022 Interne Auftragsnummer A22-02 Anschrift des Herausgebers Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Tel.: +49 221
Dapagliflozin - chronic kidney disease LoginChange the language. The current language is:English MENUVol. 3 No. 8 (2023)Reimbursement RecommendationsDapagliflozinCADTHPDFDOI: https://doi.org/10.51731/cjht.2023.718Published August 23, 2023Copyright NoticeKey MessagesThe CADTH Formulary Management Expert Committee (FMEC) concluded there was an unmet need to reduce the progression of chronic kidney disease (CKD), especially for those patients without diabetes, given the lack of reimbursed options.Evidence from the DAPA-CKD trial, the largest trial with the longest follow-up identified by a systematic review, demonstrated that patients with CKD treated with dapagliflozin had a slower decline of estimated glomerular filtration rate, a reduction in the urinary albumin to creatinine ratio
Dapagliflozin LoginChange the language. The current language is:English MENUVol. 3 No. 8 (2023)Reimbursement ReviewsDapagliflozinCADTHPDF HTMLDOI: https://doi.org/10.51731/cjht.2023.732Published September 8, 2023Copyright NoticeKey MessagesCADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives , of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses dapagliflozin propanediol monohydrate 10 mg oral tablet.Indication: To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease
Dapagliflozin (Forxiga) - symptomatic chronic heart failure Published 07 August 2023 1 Product update SMC2577 dapagliflozin film-coated tablets (Forxiga®) AstraZeneca UK Limited 07 July 2023 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs ) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission dapagliflozin (Forxiga®) is accepted for use within NHSScotland. Indication under review: in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) >40%. Dapagliflozin offers an additional treatment choice in the therapeutic class of sodium
Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Dapagliflozin (Niereninsuffizienz) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 November 2021). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-109 Dapagliflozin (kidney disease) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A21-109 Version 1.0 Dapagliflozin (kidney disease) 29 November 2021 Institute for Quality
Dapagliflozin (Forxiga) and chronic heart failure Prescrire IN ENGLISH - Spotlight ''Dapagliflozin (Forxiga°) and chronic heart failure '', 1 December 2021 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Awards * Advancing healthcare : register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Dapagliflozin (Forxiga°) and chronic heart failure SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90Spotlight * 100 most recent * ArchivesDapagliflozin (Forxiga°) and chronic heart
Dapagliflozin for chronic kidney disease Skip to main content MENUHomeRADARDapagliflozin for chronic kidney diseaseAll articles Dapagliflozin for chronic kidney diseaseA new indication and clinical criteria have been added to the PBS listing for dapagliflozin.1 September 2022 SharePrintArticleSubscribe toNPS MedicineWiseKey pointsOn 1 September 2022, a new indication and clinical criteria were added to the Authority Required (Streamlined) PBS listing for dapagliflozin (Forxiga).The new indication is for treatment of CKD and must be an addition to standard care. The patient must be stabilised on an ACE inhibitor or ARB for at least 4 weeks prior to initiation, unless contraindicated.There is a high and urgent unmet clinical need for effective CKD treatments, with limited effective therapies
Dapagliflozin for Chronic Kidney Disease Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Dapagliflozin for Chronic Kidney DiseaseCopied to clipboardDapagliflozin for Chronic Kidney Disease( Last Updated : June 10, 2022)Project Line:Health Technology ReviewProject Sub Line:Rapid Review with Expert InputProject Number:RD0065-000DetailsQuestionWhat is the clinical effectiveness of dapagliflozin for adults with chronic kidney disease?What is the cost-effectiveness of dapagliflozin for adults with chronic kidney disease?Key MessageRecent, large, high-quality trials have demonstrated some benefits of dapagliflozin for the treatment of chronic
Dapagliflozin for Chronic Kidney Disease Guidelines Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Dapagliflozin for Chronic Kidney Disease GuidelinesCopied to clipboardDapagliflozin for Chronic Kidney Disease Guidelines( Last Updated : February 9, 2022)Project Line:Reference ListProject Sub Line:Summary of AbstractsProject Number:RB1608-000DetailsQuestionWhat are the evidence-based guidelines regarding the use of dapagliflozin for the treatment of adults with chronic kidney disease?Key MessageNo relevant evidence-based guidelines were identified describing recommendations for best practice regarding the use of dapagliflozin
Dapagliflozin (Forxiga) - chronic kidney disease 1 Published 09 May 2022 1 SMC2428 dapagliflozin 10mg film-coated tablets (Forxiga®) AstraZeneca UK Ltd 8 April 2022 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission dapagliflozin (Forxiga®) is accepted for restricted use within NHSScotland. Indication under review: in adults for the treatment of chronic kidney disease. SMC Restriction: in patients with an estimated glomerular filtration rate of ≥25 to ≤75 mL/min/1.73m2 at treatment initiation, and are receiving an angiotensin converting enzyme inhibitor
Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Prescrire IN ENGLISH - Spotlight ''Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications'', 1 January 2020 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues Offers * Subscribe now * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1